Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression Of Hormones In Children With Premature Onset Puberty
Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced positive results of the ongoing Phase III extension study of SUPPRELIN(R) LA (histrelin acetate), the only once-yearly subcutaneous implant for the treatment of central precocious puberty or early onset puberty, at the Lawson Wilkins Pediatric Endocrine Society (LWPES) Annual Meeting.
More: continued here
Filed under: Endocrinology on May 15th, 2008